Wilson Disease Patients Lose a Protective Gut Microbe, Treatment May Be Why

If you or someone you love has Wilson disease, you already know the drill: a lifelong prescription for a copper-chelating drug, usually zinc acetate or D-penicillamine, to keep toxic copper from building up in the liver and brain. A new multiomics study out of three Spanish hospitals adds an uncomfortable wrinkle to that picture. It finds that Wilson disease patients are missing a gut bacterium tied to liver health, and lab experiments point to the patients' own medication as a likely reason why. Nothing here says to change a prescription, but it does hand patients a concrete, specific question to bring to their hepatologist.

Key takeaways

• Wilson disease patients showed disrupted blood chemistry and a depleted gut microbiome compared to healthy controls, including a near-loss of the beneficial bacterium Akkermansia muciniphila.
• In lab dishes, the two standard Wilson disease drugs, zinc acetate and D-penicillamine, both slowed or stopped the growth of this bacterium, apparently by starving it of copper it needs to survive.
• The human findings come from a modest cohort of 24 to 25 patients (Wilson disease is rare), and the drug-microbe cause and effect has only been shown in vitro, not yet confirmed in patients themselves.

Wilson Disease Patients Show Gut and Metabolic Disruption

Patients with Wilson disease (WD, a rare inherited disorder in which mutations in the ATP7B gene stop the body from properly clearing copper, letting it accumulate in the liver and brain) have a measurably different blood chemistry and gut microbiome than healthy people, according to a study published in iScience. Researchers led by Edna Ripollés-Campos, with senior authors Carmen Espinós and Alfonso Benítez-Páez, analyzed blood and stool from a discovery cohort of 24 to 25 WD patients across three Spanish hospitals. Blood tests turned up altered levels of amino acids, TCA-cycle compounds (the tricarboxylic acid cycle, a core set of chemical reactions cells use to generate energy) and fats, a signature accurate enough to separate WD patients from controls with an AUROC (a 0 to 1 score for how well a test tells two groups apart, where 1.0 is perfect) of 0.92 for blood metabolites and 0.83 for lipoproteins. Stool testing, meanwhile, found roughly 40 bacterial groups out of more than 3,000 examined that differed significantly between WD patients and controls, most strikingly a steep drop in Akkermansia muciniphila, a mucus-dwelling gut bacterium that other research has repeatedly linked to liver health.

Why the Gut-Liver Axis Matters in Wilson Disease

The liver and gut talk to each other constantly, a relationship researchers call the gut-liver axis, and disruptions on one side tend to show up as trouble on the other. That matters for Wilson disease, since untreated copper buildup can progress to cirrhosis and liver failure, and it matters even more for a bacterium like A. muciniphila, which past work has tied to correcting fat buildup in the blood and easing fatty liver disease. A small human safety trial already showed daily A. muciniphila supplementation was well tolerated and improved markers like insulin sensitivity and liver dysfunction indicators in overweight adults, which is part of why its disappearance in WD patients caught the researchers' attention. Alongside Akkermansia, the study also found lower levels of Christensenella, Coprococcus, and Eubacterium ruminantium, all considered beneficial, while less favorable groups like Prevotella and Megasphaera were more abundant in WD patients than in controls.

A Multi-Center Cohort With Independent Lab Validation

The study combined several methods to cross-check its findings. Blood chemistry was profiled with NMR spectroscopy and mass spectrometry, and gut bacteria were identified by sequencing the 16S rRNA gene from stool samples, in a discovery cohort of 24 to 25 WD patients matched against 25 healthy controls. The low abundance of A. muciniphila was then independently confirmed by direct DNA quantification (qPCR) in a separate validation cohort of 10 patients, and the blood chemistry signature held up in a validation group of 11 patients, correctly classifying WD status with 90% sensitivity and 88% specificity. To test whether the drugs themselves were responsible for the bacterial loss, the researchers grew a lab strain of A. muciniphila in dishes and exposed it to concentrations of zinc acetate and D-penicillamine meant to mimic the two drugs sold as Wilzin and Cupripen. Zinc acetate completely halted the bacterium's growth. D-penicillamine slowed it, tripling its doubling time and delaying growth by 5.7 hours compared to untreated cultures. Adding copper back into the D-penicillamine dishes largely restored normal growth, which told the researchers the drug was not acting as an antibiotic, it was starving the bacterium of copper it needs to function. Gene activity tests on the bacterium found roughly 30 genes affected, most of them tied to metal transport and coenzyme metabolism, consistent with a copper-shortage response.

What This Could Mean for Wilson Disease Patients

For someone managing Wilson disease, this is not a signal to change or skip medication. Chelation therapy remains the standard, effective way to prevent the organ damage copper buildup causes, and stopping it carries its own well-documented risks. What the findings do support is a specific conversation to have with a hepatologist or gastroenterologist: whether gut health, diet, or a next-generation probiotic strategy built around restoring bacteria like A. muciniphila might one day serve as a companion, not a replacement, to standard treatment. The researchers themselves frame Akkermansia restoration as an unexplored coadjuvant strategy worth testing, not a proven intervention, and no such trial in Wilson disease patients has been done yet. This kind of drug-microbiome interaction is not unique to Wilson disease either; a landmark screen of non-antibiotic drugs found a large share of them alter gut bacteria growth, so the broader lesson, that long-term medications can reshape the gut in ways doctors don't routinely check for, may extend well beyond this one rare disease.

Limits of a Small, Cross-Sectional Rare-Disease Study

Wilson disease is rare, which caps how large any cohort can realistically be, and the authors are direct about what that limits. The human-level findings come from a modest cohort of 24 to 25 patients and are cross-sectional, meaning patients were compared at a single point in time rather than tracked before and after starting treatment. Nearly all participants were already on chelation therapy, so the study could not include drug-naive patients to see what their gut microbiome looked like before treatment began. Other gaps include an imbalance between the liver-affected and neurological forms of the disease, a lack of detailed dietary-adherence tracking, and no measurement of copper levels in stool itself. Critically, the drug-microbe cause and effect, the actual mechanism connecting medication to bacterial loss, was demonstrated only in lab dishes with a single bacterial strain, not confirmed inside patients. The authors describe these limitations as restricting how confidently the links between microbiome changes, metabolic dysfunction, and disease symptoms can be interpreted as causal.

What Comes Next for Akkermansia-Based Wilson Disease Research

The research team's next step, spelled out in the paper, is to design intervention studies that test whether restoring A. muciniphila, whether through diet, prebiotics, or direct supplementation, can offset some of the metabolic and gut disruption seen in WD patients without interfering with the copper-clearing job the medications need to do. That work has not started yet, and no timeline was given. In the meantime, the immediate value of this study is diagnostic: it adds gut bacteria and blood lipid profiles to the list of measurable changes tied to Wilson disease, potentially useful for tracking disease severity or treatment response down the line.

Common Questions

What is Wilson disease? Wilson disease is a rare inherited disorder caused by mutations in the ATP7B gene that prevent the body from properly clearing copper, allowing it to build up to toxic levels in the liver and brain.

What is Akkermansia muciniphila and why does it matter here? It is a bacterium that lives in the gut's mucus layer and has been linked in other research to healthier fat metabolism and liver function; this study found it sharply reduced in Wilson disease patients.

Does this mean I should stop my Wilson disease medication? No. The study's authors do not recommend changing treatment. Chelation therapy remains the established way to prevent copper-related organ damage; the finding is worth raising with a hepatologist, not acting on alone.

Could a probiotic supplement help Wilson disease patients? Possibly, but it has not been tested. The researchers propose restoring Akkermansia muciniphila as a future companion strategy worth studying, not a therapy that has been proven to work in Wilson disease patients.

References

1. Edna Ripollés-Campos, Paula Hernández-Calderón, Martina Palomino-Schätzlein, et al. (2026). Integrated multiomics analysis reveals metabolic and microbiome alterations in Wilson disease. iScience. https://doi.org/10.1016/j.isci.2026.117101
2. Wilson Disease (NIDDK). NIH. https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease
3. Clara Depommier, Amandine Everard, Céline Druart, et al. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. https://doi.org/10.1038/s41591-019-0495-2
4. Extensive impact of non-antibiotic drugs on human gut bacteria (Nature, 2018). Nature. https://www.nature.com/articles/nature25979